Acoramidis
Trade name: Attruby
Small moleculeapprovedOrphan Drug FDA
Approved
Nov 22, 2024
Clinical trial activity
13 trials · 5 clinical orgs · 1 marketing orgs
Phase 1
3
Phase 2
8
Phase 3
7
Phase 4
2
Earliest trial started Sep 11, 2017 (NCT03294707)
Timeline
2010s
2020s
- Nov 22, 2024
Bridge BioResearch Ltd. — Earliest FDA Approval
- Nov 22, 2024
Bridge BioResearch Ltd. — NDA Organization
Indications
Approved for
Mechanism of action
- TransthyretinSTABILISER
TTR stabiliser
Approval history
- approvedNov 22, 2024
Chemistry & pharmacology
Loading structure…
SMILES
Cc1n[nH]c(C)c1CCCOc1cc(C(=O)O)ccc1F- Mol. weight
- 292.31 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3940890 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07298044 | Phase 4 | Dec 22, 2025 | Bayer |
| NCT07116473 | Phase 3 | Nov 30, 2025 | Eidos Therapeutics, Inc. |
| NCT07306949 | Phase 4 | Oct 1, 2025 | Alexion |
| NCT06563895 | Phase 3 | Oct 31, 2024 | Eidos Therapeutics, Inc. |
| NCT04988386 | Phase 3 | Oct 23, 2021 | Eidos Therapeutics, Inc. |
| NCT04882735 | Phase 3 | Sep 30, 2021 | Eidos Therapeutics, Inc. |
| NCT04958135 | Phase 1 | Jun 16, 2021 | Alexion, Celerion |
| NCT04769479 | Phase 1 | Mar 28, 2021 | Eidos Therapeutics, Inc., Quotient |
| NCT04622046 | Phase 3 | Nov 30, 2020 | Alexion, Eidos Therapeutics, Inc. |
| NCT04418024 | Phase 3 | Jun 24, 2020 | Eidos Therapeutics, Inc. |
| NCT03860935 | Phase 3 | Mar 19, 2019 | Eidos Therapeutics, Inc. |
| NCT03536767 | Phase 2 | Aug 8, 2018 | Eidos Therapeutics, Inc. |
| NCT03294707 | Phase 1 | Sep 11, 2017 | Celerion, Eidos Therapeutics, Inc. |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eidos Therapeutics, Inc. | For profit | 10 | 9 | 3 | 2017 |
| Alexion | For profit | 3 | 3 | 3 | 2020 |
| Celerion | For profit | 2 | 0 | 1 | 2017 |
| Bayer | For profit | 1 | 1 | 1 | 2025 |
| Quotient | For profit | 1 | 0 | 1 | 2021 |
5 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Bridge BioResearch Ltd. | For profit | NDA | Nov 22, 2024 |